CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Navidea Biopharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Navidea Biopharmaceuticals Inc
4100 Horizons Drive, Suite 205
Phone: (614) 793-7500p:614 793-7500 COLUMBUS, OH  43220  United States Ticker: NAVBNAVB
This company ceased filing statements with the SEC on 1/26/2024.
Business Summary
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Vice Chairman of the Board John K.Scott 68 9/14/2021 7/8/2021
Chief Financial Officer, Principal Accounting Officer CraigDais 57 8/12/2023 8/12/2023
Director Joshua M.Wilson 46 9/30/2022 9/30/2022
Independent Director Dana J.Moss 46 7/11/2023 7/11/2023
Independent Director JillStefanelli 45 6/1/2023 6/1/2023

Business Names
Business Name
Biopharmaceuticals
Europe Limited
Macrophage
6 additional Business Names available in full report.

General Information
Number of Employees: 11 (As of 3/17/2023)
Outstanding Shares: 100,084,385 (As of 11/10/2023)
Shareholders: 373
Stock Exchange: OTC
Federal Tax Id: 311080091
Fax Number: (614) 793-7520
Email Address: info@neoprobe.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024